Kyverna Therapeutics, Inc. Investors with Large Losses Are Encouraged to Contact Shareholder Rights Law Firm Robbins LLP for Information About the KYTX Class Action Lawsuit

SAN DIEGO, Dec. 26, 2024 /PRNewswire/ -- Robbins LLP reminds investors that a shareholder filed a class action against Kyverna Therapeutics, Inc. (NASDAQ: KYTX) and certain of the Company's senior executives and directors who signed the Registration Statement, effective February 7, 2024, issued in connection with the Company's initial public offering ("IPO"). Kyverna is a clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases.For more in ...